This website uses cookies to ensure you get the best experience on our website.

Evox Therapeutics and selected partners use cookies and similar technologies to ensure you get the best experience on this website. If you consent to it, we will use cookies for analytics purposes.

See our Cookie Policy to read more about the cookies we set.

You can withdraw and manage your consent at any time, by clicking "Manage cookies" at the bottom of each website page.

Select which cookies you accept

On this site, we always set cookies that are strictly necessary, meaning they are necessary for the site to function properly.

If you consent to it, we will also set other types of cookies. You can provide or withdraw your consent to the different types of cookies using the toggles below. You can change or withdraw your consent at any time, by clicking the link “Manage Cookies”, which is always available at the bottom of the site.

To learn more about what the different types of cookies do, how your data is used when they are set etc, see our Cookie Policy.

These cookies are necessary to make the site work properly, and are always set when you visit the site.

Vendors Teamtailor

These cookies collect information to help us understand how the site is being used.

Vendors Teamtailor
Evox Therapeutics career site

Careers

Connect

Join

Evox Therapeutics was established in 2016 to advance leading edge science from Oxford University and the Karolinska Institute. We work to develop innovative exosome therapeutics for diseases with significant unmet medical need.

Backed by leading venture capital groups and leveraging a comprehensive dominant intellectual property portfolio Evox’s mission is to positively impact human health by creating novel exosome-based therapeutics for the treatment of rare and severe diseases with limited treatment options for patients and their families.

We have already recruited exceptional people working in multidisciplinary teams, sharing our mission to transform how we treat rare diseases. Why not join our team and make your contribution to our journey ahead.

Timeline

1981

Cells shed vesicles

Birth of the term 'exosome' through the discovery of shed vesicles from cells.

1983

Multivesicular body formation

First description by Harding et al, of maturing reticulocytes releasing vesicles into the extracellular space

1987

Exosomes described as cell garbage release system

1996

Extracellular communication via vesicles

Landmark discovery by Raposo et al, describing vesicle-meditated transfer of antigens.

2007

Exosomal transfer of genetic material

First of several discoveries describing the transfer of mRNA and miRNA by Evs.

2011

Seminal paper published by one of Evox's founders in Nature Biotechnology

One of the most cited articles in the journal's history, showing that engineered exosomes are capable of delivering siRNA to the brain.

2016

Founded

Founded in Oxford, by Dr. Per Lundin, Professor Matthew Wood, and Dr. Samir El Andaloussi.  The company was spun out from Oxford University and the Karolinska Institute in Sweden.

2016

Series A Fundraising

£10 million raised from Oxford Sciences Innovation.

2017

First two pharma deals signed

Evox entered into two R&D pharma collaborations with global pharmaceutical companies.

2018

Moved into Medawar Lab

Evox moved into the Medawar building.

2018

Series B Fundraising

£35.5 million raised, bringing new investors into Evox Therapeutics. Redmile Group, Google Ventures, Cowen Healthcare Ventures, Panacea Ventures, and Borealis Ventures. 

2019

Innovate UK grant to advance Evox proprietary program to treat a urea cycle disorder.

2020

Takeda and Evox Therapeutics sign multi-target Rare Disease collaboration.

Lilly and Evox Therapeutics announce a multi-target RNAi and antisense research collaboration and license agreement.

Workplace & Culture

At Evox, values are at the heart of how we operate, how we behave, and how we will drive the growth of our exciting company.

We developed the values internally with all our employees, ones which we could all identify and work with.


Our Values

  • Driven to Deliver

    We are ambitious and strive to outperform on timelines and goals with no compromise on quality. We push the boundaries to change what is possible.

  • Agile and Accountable

    We show a flexible mindset in a fast paced environment. We show the ability to flex & respond promptly as required. We are accountable for our actions and take ownership for our deliverables.

  • People with Purpose

    We have pride in our work and our company. We show passion for advancing science which will provide impactful therapeutics to benefit patients.

  • Candid and Constructive

    We are open and transparent in our communication where staff have a voice and are encouraged to express their views candidly and constructively.

Benefits

  • Private Medical Cover

    Cover offered is for new and pre-existing conditions

  • Life Assurance

    Cover offered is 4 x base salary

  • Holidays

    25 days holiday plus bank holidays

  • Pension

    Employer contribution 5%, employee minimum contribution 5%, however, more than 5% can be contributed if you wish

  • Discretionary Bonus

    Bonus is payable based on a combination of corporate and personal performance

  • Evox Stock Options

    Stock Options are issued once the probationary period is passed

Our people love working here

  • I love working at Evox because I thoroughly enjoy the innovation process in a supportive and challenging environment

    Justin Hean

    Principal Scientist

  • I love working at Evox because of the open and honest communication, and the opportunities for career advancement within a diverse culture

    Tracey Richardson

    Talent Acquisition Partner

About Evox Therapeutics

 

Evox Therapeutics is harnessing and engineering the natural trafficking capabilities of extracellular vesicles to develop an entirely novel class of biotherapeutics.

 

Founded in 2016
Co-workers 110

Already working at Evox Therapeutics?

Let’s recruit together and find your next colleague.